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Anemia is a frequent complication of chronic kidney
disease, occurring in over 90% of patients undergoing re-
nal replacement therapy. The pathogenesis of the anemia
of chronic kidney disease is multifactorial, but the pre-
dominant and most consistent cause is the failure of ad-
equate production of endogenous erythropoietin (EPO)
by the kidneys. Anemia is seen early in the course of
chronic kidney disease, the decline in hemoglobin con-
centration starting at levels of creatinine clearance of
around 70 mL/min among men and 50 mL/min among
women [1]. The fundamental impact of anemia on organ
function is reduced oxygen delivery to tissues. Fatigue
and effort intolerance are the cardinal symptoms, but
other consequences such as impaired cognitive function
and concentration, sleep disorders, altered hemostasis,
depressed immune function, and impaired cardiac func-
tion are not uncommon.
Recombinant human erythropoietin (rHuEPO) was
introduced as standard therapy with the anemia of
chronic kidney disease in 1988 and immediately revo-
lutionized its management. The most dramatic improve-
ments were seen with quality of life and elimination of
the need for transfusions. Moreover, even partial correc-
tion of anemia was associated with significant improve-
ments in cardiac function. The initial targets were for
therapy to hematocrits of 30% to 33% but data to sup-
port this were limited. These target levels of hematocrit
were likely guided by the traditional view that clinically
significant anemia implied a hemoglobin level less than
10 g/dL, by concerns that higher targets may be associ-
ated with adverse effects such as seizures and hyperten-
sion and by Medicare reimbursement policies. In the fall
of 1997, the Anemia Work Group of the National Kid-
ney Foundation (NKF) published its Dialysis Outcome
Quality Initiative (DOQI) guidelines suggesting a target
hemoglobin of 11 to 12 g/dL (hematocrit of 33% to 36%)
for dialysis patients, after extensive evaluation of the lit-
erature [2]. Establishment of these anemia management
guidelines for the dialysis population improved clinical
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outcomes of mortality and hospitalization rates, but it
also became evident that there were major shortcomings
in anemia management among pre-end-stage renal dis-
ease (ESRD) patients and among those at even earlier
stages of chronic kidney disease [3–5]. With the recog-
nition of cardiovascular disease as the leading cause of
death among patients with chronic kidney disease [6],
and the role of anemia in its pathogenesis, it was appar-
ent that more attention needed to be directed toward this
powerful and potentially modifiable risk factor. The em-
phasis has since shifted to defining clinical goals of ane-
mia therapy in terms of cardiovascular disease outcomes.
This review will address the role of anemia in the patho-
genesis and progression of cardiovascular disease among
patients with chronic kidney disease and summarize re-
cent epidemiologic studies of this relationship as well as
studies evaluating the effect of anemia correction.
ANEMIA AS A PATHOGENETIC FACTOR FOR
CARDIOVASCULAR DISEASE IN CHRONIC
KIDNEY DISEASE
Tissue oxygen delivery is the most basic of physio-
logic needs and is the function of the cardiovascular and
hematopoietic systems. This was known even in the nine-
teenth century, when Bright observed that anemia was
a characteristic manifestation of chronic kidney disease
and Meischer proposed that red blood cell production
by the bone marrow could be induced by hypoxia [7].
Anemia leads to several nonhemodynamic and hemody-
namic adaptations to maintain adequate tissue oxygena-
tion. Nonhemodynamic adaptations include increases in
EPO production and in the intraerythrocytic concen-
trations of 2,3,-diphosphoglycerate (2,3-DPG). Hemody-
namic adaptations include a high cardiac output state
from an increase in cardiac preload and a decrease in
systemic vascular resistance resulting in decreased af-
terload. This leads to initial left ventricular dilatation
and increased wall tension, and ventricular remodel-
ing and hypertrophy is initiated through both hypertro-
phy of existing myofibrils and realignment of sarcom-
eres. While these changes are potentially reversible in
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Fig. 1. Mechanisms in anemia leading to myocardial damage in chronic kidney disease: Combination of factors secondary to diminished glomerular
filtration rate (GFR) and low hemoglobin. Consequences of anemia include the hemodynamic compensatory mechanisms that may turn maladaptive,
hypoxia-related injury (oxidant stress, endothelial dysfunction) and effects of erythropoietin (EPO) depletion (loss of antiapoptotic and angiogenetic
effects of EPO). Abbreviations are: RAS, renin-angiotensin system; eNOS, endothelial nitric oxide synthase.
a nonuremic milieu, several maladaptive processes in the
form of uremia-associated cardiovascular risk factors pre-
vent reversibility over time. Volume expansion, hyperten-
sion, and persistent activation of the renin-angiotensin
system (RAS), inflammation, hyperparathyroidism, and
diabetes contribute to myocardial fibrosis, calcium de-
position, left ventricular stiffness, arteriosclerosis, and
accelerated atherosclerosis. At the cellular level, hy-
poxic consequences of anemia are not restricted to
adenosine triphosphate (ATP) depletion, but release of
reactive oxygen species, and inhibition of endothelial ni-
tric oxide synthases (NOS) cause endothelial dysfunction
and vascular damage. It is now well known that EPO
is a pleiotropic cytokine with trophic functions beyond
erythropoiesis; its antiapoptotic and angiogenetic effects
have direct relevance to myocardial ischemia and vascu-
lar disease. The consequences of the anemia of chronic
kidney disease may therefore be mediated by a combina-
tion of hemodynamic changes, tissue hypoxia, and abso-
lute and relative EPO deficiency [8]. Moreover, anemia
impacts on cardiovascular disease both by its effect on
cardiac structure through the induction of left ventricu-
lar hypertrophy (LVH), and by limiting oxygen delivery
in the presence of atherosclerotic ischemic lesions [9].
Figure 1 summarizes the mechanisms of myocardial dam-
age due to anemia in the setting of chronic kidney disease,
leading to the clinical consequences of congestive heart
failure and coronary disease.
ANEMIA, CHRONIC KIDNEY DISEASE,
AND CARDIOVASCULAR DISEASE:
A CRITICAL TRIAD
Anemia, chronic kidney disease, and cardiovascular
disease are closely linked in their pathogenesis and
evolution. Chronic kidney disease is recognized as an in-
dependent risk factor for cardiovascular disease and is
associated with a clustering of cardiovascular risk factors,
both traditional and non-traditional, that have a cumu-
lative impact as chronic kidney disease progresses over
time [10]. This temporal relationship is true of anemia
as well, which begins early and tracks with the decline
in glomerular filtration rate (GFR) and the evolution of
cardiovascular disease.
In 2002, Silverberg et al [11] proposed the concept of
a cardiorenal anemia syndrome to emphasize that ane-
mia, chronic kidney disease, and congestive heart fail-
ure form a self-perpetuating triad (Fig. 2) and interact to
translate into mortality multipliers. While it is well known
that chronic kidney disease predisposes to cardiovascu-
lar disease and eventually congestive heart failure, it is
also being appreciated that congestive heart failure and
anemia are themselves major contributors to the deteri-
oration of kidney function. Congestive heart failure con-
tributes to diminished kidney tissue perfusion, which acti-
vates cascades of kidney tissue injury due to oxidant stress
and cytokines. Anemia could accelerate progression of
kidney disease by at least two mechanisms, directly by
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Fig. 2. Self-perpetuating triad formed by the interactions among ane-
mia, chronic kidney disease (CKD) and congestive heart failure (CHF)
that mutually potentiate each other and translate into mortality multi-
pliers.
kidney tissue hypoxia and indirectly by inducing car-
diac failure, decrease in kidney blood flow, and thereby
decreased tissue perfusion and oxygen delivery. Kid-
ney hypoxia is associated with up-regulation of hypoxia-
inducible factors (HIF)-1a and -2a, collagen genes and
matrix metalloproteinases (MMPs), setting the stage for
progressive injury to the interstitium. HIF-1a is a tran-
scriptional regulator of the EPO gene, as well as of
extracellular matrix, heme oxygenase, NOS, and apop-
tosis genes. An additional mechanism of kidney dam-
age is through hypoxia-induced sympathetic activation
that could potentially worsen proteinuria and glomeru-
losclerosis [12]. While anemia can cause congestive heart
failure, the converse relationship of congestive heart fail-
ure as a cause of anemia is less intuitive. Congestive
heart failure is associated with elevated levels of proin-
flammatory cytokines that could stem from injured my-
ocardium, tissue hypoxia, hepatic congestion, and bowel
ischemia and inhibit hematopoiesis. Congestive heart
failure is also associated with malnutrition and hypoal-
buminemia that results from either anorexia and poor
intake or depressed hepatic synthetic function from
inflammation. Other mechanisms by which congestive
heart failure potentiates anemia include the use of
angiotensin-converting enzyme (ACE) inhibitors that
could suppress EPO production, use of aspirin that could
promote gastrointestinal blood loss, and hemodilution
[8, 11].
ANEMIA IN CHRONIC KIDNEY DISEASE:
MAGNITUDE OF THE PROBLEM
Given the high prevalence of chronic kidney disease
and the decline in hemoglobin concentration with even
modest reductions in kidney function, anemia of chronic
kidney disease is a substantial public health burden. In-
deed, Hsu et al [1] have recently estimated that 800,000
adults have anemia (defined as hemoglobin <11 g/dL) as-
sociated with chronic kidney disease in the United States.
Likewise, applying data on the distribution of hematocrit
levels among patients with various degrees of chronic kid-
ney disease, from a Health Maintenance Organization to
the 1990 United States population of 248,709,873 (1990
United States Census), we estimated that there were ap-
proximately 1.5 million individuals with chronic kidney
disease in the United States who were anemic, of whom 1
million had hematocrit levels <33% [13]. Even at serum
creatinine levels of ≤2 mg/dL, 45% of patients have a
hematocrit concentration of <36% and 8% have a hema-
tocrit <30%. The estimated decline in hematocrit for
every 10 mL/min/1.73 m2 decrease in estimated GFR
was 3% [3].
The burden of anemia is compounded not only by the
prevalence of chronic kidney disease but by its under-
recognition and undertreatment. Despite the availability
of rHuEPO for more than a decade, recent studies have
shown a high prevalence of anemia among patients with
ESRD at initiation of dialysis. In a large cohort of pa-
tients who began chronic dialysis in the United States
between April 1995 and June 1997, 51% of patients had
hematocrit levels less than 28% and 67% had hematocrit
levels less than 30%. Overall, only 23% of patients had
received rHuEPO before the initiation of dialysis, and
among patients with hematocrit levels less than 28%, only
20% had received rHuEPO [4]. Other studies showed a
similar pattern of undertreatment of anemia in patients
with chronic kidney disease who have yet to progress
to ESRD. For example, in a recent, large, retrospective
chart survey of patients with chronic kidney disease in the
predialysis phase, 59% had hematocrit <36% and 15%
had hematocrit <30% at their first visit to a nephrologist,
but only 8% received rHuEPO. During follow-up by the
nephrologist, the proportion of patients with hematocrit
<36% increased to 78%, and the proportion with hema-
tocrit <30% increased to 39%. Despite the prevalence
and severity of anemia, only 30% of patients overall, and
55% of patients with hematocrit <30% were receiving
rHuEPO [3]. Trends in anemia at initiation of dialysis in
the United States are equally disturbing. In 1995, prior
to the release of the NKF-DOQI guidelines, the mean
hematocrit at initiation of dialysis was only 28.1% and
showed virtually no improvement since (mean hemat-
ocrit 29.3% in 1999). Consequently, roughly two thirds of
patients began renal replacement therapy at hematocrit
levels well below the currently recommended threshold
levels of 33% [5]. While mean hematocrit in the United
States dialysis population have increased steadily since
1990, particularly after the release of the NKF-DOQI
guidelines, the mean hematocrit values at start of dialysis
have remained essentially unchanged [14].
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Table 1. Interventional studies showing partial regression of left ventricular hypertrophy after partial correction of anemia
Change in hemoglobin g/dL/ Change in left ventricular mass
hematocrit% (mean ± SD) index g/m2 (mean ± SD)
Study Number
Dialysis/
Predialysis
Duration of
rHuEPO therapy Before After Before After P value
Zehnder et al [44] 12 Dialysis 18.8 ± 2.7 months 8.6 ± 0.7 g/dL 11.4 ± 1.2 g/dL 222.7 ± 41.0 155.4 ± 25.1 <0.001
Portoles et al [45] 11 Predialysis 6 months 9.0 ± 0.3 g/dL 11.7 ± 0.4 g/dL 178.2 ± 20.6 147.3 ± 20.6 trend
London et ala [46] 153 Dialysis 54.0 ± 37.0 months 8.7 ± 1.7 g/dL 10.5 ± 1.5 g/dL 290.0 ± 80.0 264.0 ± 86.0 <0.01
Hayashi et alb [47] 9 Predialysis 10 months 23.6% ± 0.5% 39.1 ± 0.8% 140.6 ± 12.1 111.2 ± 8.3 <0.01
Wizemann et al [48] 28 Dialysis 16 months <25% 35% 199.0 ± 35.0 160.0 ± 2.8 <0.001
Silberberg et ala [49] 22 Dialysis 8 months 6.3 ± 0.8 g/L 11.4 ± 1.5 g/L 253.0 ± 77.0 215.0 ± 71.0 <0.001
rHuEPO is recombinant human erythropoietin.
aLeft ventricular mass and not left ventricular mass index.
bResults expressed as mean ± SEM.
ANEMIA AS A PREDICTOR OF PROGRESSION
OF CHRONIC KIDNEY DISEASE IN
CLINICAL STUDIES
With anemia being very closely associated with kid-
ney disease it has been difficult to differentiate anemia
as cause or effect in observational studies of progres-
sive kidney disease. A large retrospective survey from
the Okinawa Dialysis Registry indicated that individu-
als in the general population with low hematocrit had
a significantly elevated risk of subsequent ESRD after
a mean follow-up of over 10 years [15]. The results of a
small randomized trial of rHuEPO among predialysis pa-
tients suggested that anemia correction delayed the time
to doubling of serum creatinine [16]. In the Reduction in
End Points in NIDDM with the Angiotensin II Antag-
onist Losartan (RENAAL) Study, type II diabetics with
nephropathy, who had lower baseline hemoglobin con-
centrations had a greater prevalence of ESRD events, and
of kidney events (defined as a composite of doubling of
serum creatinine or ESRD) independent of their kidney
function and proteinuria levels, and the risk associated
with hemoglobin levels increased as hemoglobin concen-
tration decreased. While this finding, that a modest de-
gree of anemia in type 2 diabetic patients with nephropa-
thy affects the progression of kidney disease is novel, it
does not distinguish between anemia as a risk marker or
pathogenetic factor, and does not address the scope of
anemia correction in benefiting chronic kidney disease–
related outcomes [17].
ANEMIA AS A PREDICTOR OF
CARDIOVASCULAR DISEASE
IN CHRONIC KIDNEY DISEASE:
WHAT IS THE EVIDENCE
Among patients with chronic kidney disease, anemia
influences both the pathogenesis of and adverse out-
comes from cardiovascular disease. Clinical studies have
addressed the relationship of anemia to LVH, congestive
heart failure, and ischemic heart disease.
Anemia and LVH
The anemia of early-stage chronic kidney disease con-
tributes to the development of LVH, which in itself is
an independent determinant of mortality among patients
with ESRD. Foley et al [18] reported a 75% prevalence
of LVH in patients starting ESRD therapy. In a cross-
sectional study, Levin et al [19] reported that the preva-
lence of LVH detected by echocardiography was 26.7%
in patients with creatinine clearance >50 mL/min, 30.8%
in those with clearances between 25 and 49 mL/min, and
45.2% in those with clearance <25 mL/min. In a multi-
variate analysis, the independent risk of LVH was 32%
higher for every 0.5 g/dL decrease in hemoglobin con-
centration [20]. Table 1 summarizes several studies that
have shown partial regression of LVH after partial cor-
rection of anemia in dialysis patients. These observations
support the etiological role of anemia and suggest that
these abnormalities can be reduced or prevented by ap-
propriate early management of anemia and hypertension.
This question will also be investigated in The Cardiovas-
cular Risk Reduction by Early Anemia Treatment with
Epoetin Beta (CREATE) Trial [21]. This is an open, ran-
domized, parallel-group, multicenter (Europe, Mexico,
Taiwan, and Thailand) study that will compare the change
in left ventricular mass index after 1 year and time to first
cardiovascular event between an early intervention group
with anemia correction initiated at a hemoglobin of 11.0
to 12.5 g/dL to a target of 13 to 15 g/dL, and a late in-
tervention group where anemia correction will begin at a
hemoglobin <10.5 g/dL, to achieve a target hemoglobin
of 10.5 to 11.5 g/dL.
Anemia and congestive heart failure
Foley et al [22] examined the impact of anemia on car-
diomyopathy, morbidity and mortality in a cohort of 432
Canadian dialysis patients who were followed prospec-
tively for an average of 41 months. CHF was present
in 31% of patients and after adjustments for age, dia-
betes, ischemic heart disease, blood pressure, and serum
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albumin level, a decrease in hemoglobin concentration of
1 g/dL was found to be associated with a 49% increased
likelihood of left ventricular dilatation, a 55% increased
likelihood of poor ejection fraction, and a 14% increased
likelihood of death from cardiovascular disease after start
of renal replacement therapy. As well as being prevalent
in chronic kidney disease, anemia is a common feature
among patients with congestive heart failure. In a retro-
spective analysis of 142 ambulatory patients with conges-
tive heart failure, over half were anemic (haemoglobin
<12 g/dL) and more severe degrees of congestive heart
failure by the New York Heart Association (NYHA) clas-
sification were associated with both lower hemoglobin
and higher serum creatinine levels [23]. The Study of
Left Ventricular Dysfunction (SOLVD) involving 6967
patients with an ejection fraction <35% and serum crea-
tinine ranging between 0.4 and 2.5 mg/dL, demonstrated
that survival rates were highest with hematocrit of 40%
or greater, with progressively poorer survival as hema-
tocrit fell. The hazard ratio for mortality increased by
3% for a one unit fall in hematocrit and by 6% for ev-
ery 10 mL/min decrease in GFR [24]. McClellan et al
[25] extended these observations to a community set-
ting, and found that nearly half of all patients admitted
with a diagnosis of congestive heart failure had a hema-
tocrit <36%. The 1-year death rates among individuals
with and without chronic kidney disease were 44.9% and
31.4%, respectively. Relative to individuals with a hemat-
ocrit ≥40%, who had an adjusted mortality (for age, gen-
der, race, kidney function, and cardiovascular comorbidi-
ties) at 1 year of 31.2%, those with a hematocrit <30%
had an adjusted mortality of 50%. The impact of anemia
as a mortality risk multiplier was more comprehensively
shown by Gilbertson et al [26] in a 5% sample of Medi-
care recipients aged 65 years or older. The relative risk of
death in patients with chronic kidney disease increased
from 2.0 to 3.7 if anemia was also present and from 2.9 to
4.0 in patients with congestive heart failure if anemia was
also present. The presence of all three conditions in an
individual increased the risk of death to 6.0 [26]. Li and
Collins [27] studied Medicare data for 50,579 hemodial-
ysis patients incidence during 1998 and 1999. Compared
to patients with hematocrit values of >33% to 36%, pa-
tients with values of >36% to 39% and values of >39%
had lower risk ratios for death due to cardiac disease of
0.92 and 0.83, respectively.
Treatment of even mild degrees of anemia has shown
benefit in severe congestive heart failure independent of
the underlying level of kidney function. Silverberg et al
[28] randomized 32 patients with left ventricular ejection
fraction ≤40% and ≥NYHA class III to treatment with
rHuEPO and intravenous iron or usual management. In-
crease in hemoglobin in the treatment group from a mean
hemoglobin of 10.3 g/dL to 12.9 g/dL was associated with
an improvement of 42% in the NYHA class compared
to the control group where the NYHA class worsened
by 11%. Other studies using administrative data showed
that EPO use in the predialysis phase was associated with
lower 1-year mortality after initiation of dialysis in inci-
dent dialysis patients (reviewed in [29]).
Anemia and ischemic heart disease
Chronic kidney disease is associated with a higher
prevalence of ischemic heart disease, and increases the
risk of death among individuals with preexisting coro-
nary disease [10, 30]. In an incident dialysis cohort, the
prevalence of either angina or myocardial infarctions was
noted to be 22% [10]. Langston et al [31] studied a ran-
dom sample of patients admitted to the hospital with a
principal diagnosis of acute myocardial infarction, in a
single southern state of the United States. They noted a
prevalence of chronic kidney disease of 60%, and found
that anemia significantly increased the risk of death at
one year from 18.6% for individuals with a hematocrit
>40% to 35.8% for individuals with a hematocrit <30%.
Anemia and diabetic kidney disease
Approximately 40% of patients with reduced GFR
have diabetes mellitus and cardiovascular disease risks
are markedly exaggerated in patients with diabetic kid-
ney disease. Patients with end-stage diabetic nephropa-
thy have a significantly greater risk of cardiovascular
mortality than patients without diabetes, and a greatly el-
evated risk of developing new-onset ischemic heart dis-
ease; the incidence of LVH and cardiovascular disease
is also greater [32]. Diabetics fall into a category of in-
creased risk even before GFR begins to decline and the
National Cholesterol Education Program (NCEP) Adult
Treatment Panel III recommends that diabetes be con-
sidered a coronary heart disease equivalent [33]. Ane-
mia develops earlier in diabetics and tends to be more
severe than in patients with nondiabetic chronic kidney
disease. Bosman et al [34] found that 50% of a group of
patients with diabetic nephropathy had anemia compared
with none of a group of patients with glomerulonephritis,
matched for serum creatinine level. It has been postu-
lated that EPO deficiency arises earlier in diabetes due
to the early involvement of the kidney interstitial com-
partment. Alternatively, as release of EPO is modulated
by the sympathetic nervous system, autonomic neuropa-
thy may play a role.
Two ongoing trials, The Trial to Reduce Cardiovas-
cular Events with Aranesp Therapy (TREAT) and
the Anemia Correction in Diabetes (ACORD) will use
darbepoeitin alfa (Aranesp) and epoetin beta (Neo-
Recormon), respectively, in diabetics with chronic kid-
ney disease to correct anemia to a target of 12.0 g/dL or
above. The end points are, respectively, cardiovascular
events (fatal and nonfatal) and change in left ventricular
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mass index, and will evaluate the benefits of anemia cor-
rection in early diabetic nephropathy on cardiovascular
risk reduction [35, 36].
ANEMIA AND RESOURCE UTILIZATION
Both chronic kidney disease and cardiovascular dis-
ease are conditions associated with higher utilization of
health care resources [37] and anemia would be expected
to increase costs. Several analyses of Medicare data for
incident hemodialysis patients have shown that com-
pared with reference patients with hematocrits of 30%
to <33%, the Medicare-allowable per patient per month
(PPPM) expenditures were significantly greater for pa-
tients with hematocrit <27% and 27% to <30% (12. 7%
and 5.3%, respectively), and significantly less for patients
with hematocrit of 33% to <36% and 36% and >(6.0%
and 8.2%, respectively). Hospitalization rates in the high-
est hematocrit group were also 16% to 22% lower [27,
38]. The same investigators also found that patients who
received no EPO therapy in the predalysis period tended
to have more hospitalizations and higher PPPM expen-
diture during the first 6 months after initiation of renal
replacement therapy [29]. Among chronic kidney disease
patients in an outpatient nephrology setting, we found
that higher hematocrit were associated with a lower risk
of hospitalization and less hospital days [39].
ANEMIA MANAGEMENT IN CHRONIC
KIDNEY DISEASE: CONTROVERSIES
AND COMPLEXITIES
Anemia is a modifiable risk factor that readily responds
to treatment with rHuEPO. Before its introduction, red
blood cell transfusions were the only effective means
of correcting anemia. With the introduction of darbepo-
etin alfa (Aranesp), a unique erythropoiesis-stimulating
protein, with a half-life approximately three times longer
than that of rHuEPO, there is an effective range of ery-
thropoietic agents to provide the maximal flexibility, ben-
efit and efficacy to the patient with chronic kidney disease
[40]. Although there is abundant observational evidence
regarding the benefit of higher hematocrit, normaliza-
tion of hemoglobin has not shown unequivocal survival
benefit. In the Canadian multicenter study complete cor-
rection of anemia did not induce complete regression
of concentric LVH, but it appeared to prevent left ven-
tricular dilatation in those with normal left ventricular
volume. The United States Normal Hematocrit Trial ac-
tually showed a higher mortality with complete correc-
tion of anemia among patients with preexisting cardiac
disease. An analysis of Medicare data showed that mor-
tality risk was unchanged with increasing hematocrit to
36% to 39%, although hospitalizations decreased. The
present consensus regarding the goals of anemia manage-
ment therefore recommends individualization of targets
in the context of age, functional status, and presence of
cardiac disease (reviewed in [41]). Both the NKF-DOQI
and the European Best Practice Guidelines establish a
minimum threshold hemoglobin of 11 g/dL for evalua-
tion and intervention, but the latter also features an open-
ended target hemoglobin that provides for normalization
of hemoglobin where clinically appropriate [42].
Because of the growing body of scientific literature on
the significant morbidity and mortality associated with
the anemia of chronic kidney disease, a Renal Anemia
Management Period (RAMP) has been proposed [43].
The RAMP is defined as the time following onset of
chronic kidney disease when anemia develops, and needs
early diagnosis and treatment, which would achieve the
goals of delaying disease progression, minimizing cardio-
vascular complications, and enhancing quality of life. Sev-
eral large trials are now underway to address the effect of
correction of anemia during the earlier stages of chronic
kidney disease before significant cardiac damage has oc-
curred, an intervention that might well be the holy grail of
improved long-term survival among patients with chronic
kidney disease.
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